Amphastar Pharmaceuticals, Inc. (AMPH)
21.51
-0.09
(-0.42%)
USD |
NASDAQ |
Aug 24, 16:00
21.51
0.00 (0.00%)
After-Hours: 20:00
Amphastar Pharmaceuticals Enterprise Value : 1.314B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 1.314B |
| August 20, 2026 | 1.318B |
| August 19, 2026 | 1.320B |
| August 18, 2026 | 1.303B |
| August 17, 2026 | 1.283B |
| August 14, 2026 | 1.285B |
| August 13, 2026 | 1.254B |
| August 12, 2026 | 1.246B |
| August 11, 2026 | 1.264B |
| August 10, 2026 | 1.260B |
| August 07, 2026 | 1.280B |
| August 06, 2026 | 1.238B |
| August 05, 2026 | 1.257B |
| August 04, 2026 | 1.242B |
| August 03, 2026 | 1.256B |
| July 31, 2026 | 1.244B |
| July 30, 2026 | 1.263B |
| July 29, 2026 | 1.271B |
| July 28, 2026 | 1.253B |
| July 27, 2026 | 1.212B |
| July 24, 2026 | 1.192B |
| July 23, 2026 | 1.198B |
| July 22, 2026 | 1.217B |
| July 21, 2026 | 1.229B |
| July 20, 2026 | 1.231B |
| Date | Value |
|---|---|
| July 17, 2026 | 1.236B |
| July 16, 2026 | 1.240B |
| July 15, 2026 | 1.221B |
| July 14, 2026 | 1.196B |
| July 13, 2026 | 1.216B |
| July 10, 2026 | 1.192B |
| July 09, 2026 | 1.205B |
| July 08, 2026 | 1.199B |
| July 07, 2026 | 1.250B |
| July 06, 2026 | 1.230B |
| July 02, 2026 | 1.231B |
| July 01, 2026 | 1.251B |
| June 30, 2026 | 1.254B |
| June 29, 2026 | 1.316B |
| June 26, 2026 | 1.364B |
| June 25, 2026 | 1.331B |
| June 24, 2026 | 1.330B |
| June 23, 2026 | 1.264B |
| June 22, 2026 | 1.210B |
| June 18, 2026 | 1.232B |
| June 17, 2026 | 1.258B |
| June 16, 2026 | 1.283B |
| June 15, 2026 | 1.272B |
| June 12, 2026 | 1.289B |
| June 11, 2026 | 1.308B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Supernus Pharmaceuticals, Inc. | 2.335B |
| Liquidia Corp. | 6.013B |
| ANI Pharmaceuticals, Inc. | 1.966B |
| Corcept Therapeutics, Inc. | 12.89B |
| Veru, Inc. | 21.90M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 30.35M |
| Revenue (Quarterly) | 183.90M |
| Total Expenses (Quarterly) | 153.56M |
| EPS Diluted (Quarterly) | 0.6862 |
| Gross Profit Margin (Quarterly) | 48.73% |
| Profit Margin (Quarterly) | 16.50% |
| Earnings Yield | 7.93% |
| Operating Earnings Yield | 11.46% |
| Normalized Earnings Yield | 7.024 |